Epzicom (Abacavir/3TC, Kivexa)
- Epzicom/Kivexa (Abacavir + Lamivudine) (November 29, 2012)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Epzicom (Abacavir/3TC, Kivexa) (September 13, 2012)
From AIDSinfo
- Epzicom (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FAQs About Epzicom (Abacavir/3TC, Kivexa) (January 1, 2012)
From The Body's "Ask the Experts" Forums
- Patient Information About Epzicom (Abacavir/3TC, Kivexa) (PDF) (November 2011)
From ViiV Healthcare
- Switch to HIV Combo Pill May Improve Lipids (September 15, 2010)
From MedPage Today
- Lipids Drop After Switch From ABC/3TC/Efavirenz to Atripla (September 15, 2010)
From National AIDS Treatment Advocacy Project
- ACTG 5202: Four Drugs Enter (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- ACTG 5202: No Significant Difference in Time to Failure Between Kivexa and Truvada in Patients With Lower Viral Loads When Paired With Efavirenz or Atazanavir (February 18, 2010)
From aidsmap.com
- Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
- GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
- Epzicom (Epivir + Ziagen) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
On TheBodyPRO.com
- Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
- Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group
On TheBodyPRO.com
- FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
|
Advertisement
|
Email
Glossary
